Search hospitals > New Mexico > Albuquerque
Presbyterian Kaseman Hospital
Claim this profileAlbuquerque, New Mexico 87110
Global Leader in Breast Cancer
Global Leader in Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Colorectal Cancer
80 reported clinical trials
12 medical researchers
Summary
Presbyterian Kaseman Hospital is a medical facility located in Albuquerque, New Mexico. This center is recognized for care of Breast Cancer, Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Colorectal Cancer and other specialties. Presbyterian Kaseman Hospital is involved with conducting 80 clinical trials across 207 conditions. There are 12 research doctors associated with this hospital, such as Atul Kumar, Ursa A. Brown-Glaberman, Carolyn Y. Muller, and Colleen C. McCormick.Area of expertise
1Breast Cancer
Global LeaderER positive
Stage IV
HER2 negative
2Cancer
Global LeaderStage III
Stage IV
Stage II
Top PIs
Atul KumarUniversity of New Mexico Cancer Center4 years of reported clinical research
Expert in Lung Cancer
Expert in Non-Small Cell Lung Cancer
22 reported clinical trials
38 drugs studied
Ursa A. Brown-GlabermanUniversity of New Mexico Cancer Center4 years of reported clinical research
Studies Breast Cancer
Studies Cancer
20 reported clinical trials
45 drugs studied
Carolyn Y. MullerUniversity of New Mexico Cancer Center1 year of reported clinical research
Studies Cancer
Studies Recurrence
20 reported clinical trials
41 drugs studied
Colleen C. McCormickLegacy Good Samaritan Hospital and Medical Center4 years of reported clinical research
Studies Ovarian Cancer
Studies Fallopian Tube Cancer
13 reported clinical trials
44 drugs studied
Clinical Trials running at Presbyterian Kaseman Hospital
Breast Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Gallbladder Cancer
Prostate Cancer
Cancer
Colorectal Cancer
Lymphoma
Multiple Myeloma
Squamous Cell Carcinoma
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Support Program
for Breast Cancer
This phase III trial compares an additional support program (text message reminders and/or telephone-based counseling) with usual care in making sure breast cancer patients take their endocrine therapy medication as prescribed (medication adherence). Medication adherence is how well patients take the medication as prescribed by their doctors, and good medical adherence is when patients take medications correctly. Poor medication adherence has been shown to be a serious barrier to effective treatment for hormone receptor positive breast cancer patients. Adding text message reminders and/or telephone-based counseling to usual care may increase the number of days that patients take their endocrine therapy medication as prescribed.
Recruiting2 awards Phase 34 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Presbyterian Kaseman Hospital?
Presbyterian Kaseman Hospital is a medical facility located in Albuquerque, New Mexico. This center is recognized for care of Breast Cancer, Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Colorectal Cancer and other specialties. Presbyterian Kaseman Hospital is involved with conducting 80 clinical trials across 207 conditions. There are 12 research doctors associated with this hospital, such as Atul Kumar, Ursa A. Brown-Glaberman, Carolyn Y. Muller, and Colleen C. McCormick.